1. Home
  2. PRME vs SATL Comparison

PRME vs SATL Comparison

Compare PRME & SATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$3.49

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$3.86

Market Cap

529.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
SATL
Founded
2019
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
529.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
PRME
SATL
Price
$3.49
$3.86
Analyst Decision
Buy
Strong Buy
Analyst Count
14
5
Target Price
$7.11
★ $10.20
AVG Volume (30 Days)
4.6M
★ 4.9M
Earning Date
11-06-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
★ 85.94
EPS
★ N/A
N/A
Revenue
$4,632,000.00
★ $17,707,000.00
Revenue This Year
$90.65
$166.10
Revenue Next Year
$19.47
$32.37
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 55.28
37.58
52 Week Low
$2.67
$1.26
52 Week High
$6.30
$12.00

Technical Indicators

Market Signals
Indicator
PRME
SATL
Relative Strength Index (RSI) 53.22 32.06
Support Level $2.88 $3.34
Resistance Level $3.64 $6.18
Average True Range (ATR) 0.34 0.36
MACD 0.02 -0.19
Stochastic Oscillator 52.38 1.94

Price Performance

Historical Comparison
PRME
SATL

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

Share on Social Networks: